Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC53856 vs rHuEPO in Chemotherapy-induced Anemia
NCT07891377Phase 2Not yet recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HEC53856 in Chemotherapy-induced anemia (CIA) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Hemoglobin compliance rate at 7 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HEC53856
03
Conditions
Chemotherapy-induced anemia (CIA)
Beyond the preview
Go deeper on NCT07891377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891377.